Endocrine Abstracts

Dyslipidemia is a frequent pathology, especially in diabetics, which may require the use of lipid-lowering drugs such as statins. Our goal is to determine the impact of these molecules on the metabolic profile of a diabetic population with dyslipidemia.

Methods: This is a retrospective study including 150 patients followed at the Tunis nutrition institute for diabetes and dyslipidemia.

Results: The average BMI was 31.4 ± 6.1 kg/m². Waist circumference was high especially among women. Over three-quarters (76%) of the patients were hypertensive. Average fasting glucose was 13.12 mmol/l with extremes ranging from 5.3 to 24.9 mmol/l. The average HbA1c level was 9.62 ± 2.16%. The mean duration of statin therapy was 2.2 ± 2.6 years. After being put on statins, the average BMI and waist circumference both increased significantly (P = 0.007 and P = 0.029 respectively). Both systolic and diastolic blood pressure increased but not significantly. Fasting blood sugar became significantly higher (P = 0.039). The average HbA1c decreased but this decrease was not significant. Regarding lipid parameters, total cholesterol decreased by 1.02 ± 1.25 mmol/l (P < 0.001). Triglyceridemia decreased but not significantly (P = 0.15). HDL cholesterolemia decreased by 0.035 ± 0.27 mmol/l without this being significant. The uricemia also decreased under statins but not significantly.

Conclusion: Statins have modified the metabolic profile of our population, especially anthropometric and biological parameters, which underlines the importance of clinical and biological monitoring after taking these molecules.